ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 20 July 2009

Endocrine-Related Cancer 2009;16:1103.

DOI: 10.1677/ERC-09-0087
Copyright © 2009 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
ERC-09-0087v1
16/4/1103    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vigneri, P.
Right arrow Articles by Vigneri, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vigneri, P.
Right arrow Articles by Vigneri, R.

REVIEW

Diabetes and cancer

Paolo Vigneri, Francesco Frasca, Laura Sciacca, Giuseppe Pandini and Riccardo Vigneri

P Vigneri, Department of Biomedical Sciences, Section of General Pathology, University of Catania, Catania, Italy
F Frasca, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
L Sciacca, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
G Pandini, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
R Vigneri, Internal Medicine, Endocrinology, Catania, 95122, Italy

Correspondence: Riccardo Vigneri, Email: vigneri{at}unict.it

Abstract

Diabetes and Cancer are two heterogeneous, multifactorial, severe and chronic diseases. Because of their frequency, reciprocal influences, even if minor, may have a major impact.

Epidemiological studies clearly indicate that the risk for several types of cancer (including pancreas, liver, breast, colorectal, urinary tract and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased.

Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with preeminent metabolic but also mitogenic effects and its action in malignant cells is favored by mechanisms acting both at the receptor and post-receptor level. Obesity, hyperglycemia and increased oxidative stress may also contribute to increased cancer risk in diabetes.

While antidiabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and antiandrogens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors.

In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.




This article has been cited by other articles:


Home page
DiabetesHome page
R. Vigneri, L. Sava, S. Squatrito, and L. Sciacca
Comment on: Yang et al. (2010) Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry. Diabetes;59:1254-1260
Diabetes, November 1, 2010; 59(11): e24 - e24.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
M. Toi, Y. Ohashi, A. Seow, T. Moriya, G. Tse, H. Sasano, B. W. Park, L. W. C. Chow, A. V. Laudico, C. H. Yip, et al.
The Breast Cancer Working Group Presentation was Divided into Three Sections: The Epidemiology, Pathology and Treatment of Breast Cancer
Jpn. J. Clin. Oncol., September 1, 2010; 40(suppl_1): i13 - i18.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee
Diabetes and Cancer: A consensus report
Diabetes Care, July 1, 2010; 33(7): 1674 - 1685.
[Full Text] [PDF]


Home page
CA Cancer J ClinHome page
E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee
Diabetes and Cancer: A Consensus Report
CA Cancer J Clin, July 1, 2010; 60(4): 207 - 221.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. Hemminki, X. Li, J. Sundquist, and K. Sundquist
Risk of Cancer Following Hospitalization for Type 2 Diabetes
Oncologist, June 1, 2010; 15(6): 548 - 555.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
H. C. Gerstein
Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?
JAMA, February 3, 2010; 303(5): 446 - 447.
[Full Text] [PDF]


Home page
The OncologistHome page
C. R. Chong and B. A. Chabner
Mysterious Metformin
Oncologist, December 1, 2009; 14(12): 1178 - 1181.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Society for Endocrinology.